Corcept Therapeutics is trading at $109.28, down 5.87% in pre-market, with no clear company-specific announcement identified to explain the decline.
- The Nasdaq is down 1.00% in the supplied market context, which may be contributing to pressure; available evidence does not establish a direct cause.
- The latest listed company news predates September 28.
- Pre-market volume was not provided, so activity versus normal levels cannot be assessed.